Stock of Jade Biosciences, Inc. (JBIO) is dropping about 12 percent in Monday morning trading despite the company's positive report from a Phase 1 trial evaluating JADE101 for the treatment of immunoglobulin A nephropathy.
The company's stock is currently trading at $18.35, down 12.77 percent or $2.69, over the previous close of $21.04 on the Nasdaq. It has traded between $6.57 and $28.00 in the past one year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.